CliffBio
small molecule

MYFORTIC

MYCOPHENOLATE SODIUM

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameMYFORTIC
Active ingredientMYCOPHENOLATE SODIUM
StrengthEQ 360MG BASE
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2004
Marketing statusRX

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.